Related Experiment Video

Updated: Nov 2, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.5K

Carvedilol improves left ventricular diastolic dysfunction in patients with transfusion-dependent thalassemia

Suchaya Silvilairat1, Pimlak Charoenkwan1, Suwit Saekho2,3

  • 1Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Annals of Pediatric Cardiology
|June 9, 2021
PubMed

Insights

Carvedilol improved diastolic dysfunction in thalassemia patients with iron overload. This treatment shows promise for heart health in transfusion-dependent thalassemia, but further studies are needed.

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Iron overload cardiomyopathy is a primary cause of mortality in patients requiring frequent blood transfusions for thalassemia.
  • Left ventricular diastolic dysfunction is a common complication in these patients.

Purpose of the Study:

  • To evaluate the effectiveness of carvedilol in improving left ventricular diastolic dysfunction in transfusion-dependent thalassemia patients.
  • To assess changes in cardiac function and iron levels following carvedilol treatment.

Main Methods:

  • Eighteen transfusion-dependent thalassemia patients with left ventricular diastolic dysfunction and normal systolic function received carvedilol (0.8 mg/kg/day).
  • Echocardiography and magnetic resonance imaging were used to assess ventricular function and cardiac iron levels at baseline, 3 months, and 6 months.

Main Results:

  • The study included patients aged 13-25 years, with 14 having Grade II and 4 having Grade III diastolic dysfunction.
  • Carvedilol treatment led to significant improvement in left ventricular diastolic dysfunction within 3 months.
  • Doppler parameters related to diastolic function showed significant reductions after 3 months of carvedilol therapy.

Conclusions:

  • Three months of carvedilol treatment improved Doppler parameters of left ventricular diastolic function in transfusion-dependent thalassemia patients without systolic dysfunction.
  • Further double-blind controlled studies are necessary to confirm these findings and their clinical implications.
Abstract

Keywords:
CARDIAC T2*carvediloltissue Doppler echocardiographytransfusion-dependent thalassemia

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K
Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.3K

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
111
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
93
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
538
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
840
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
60
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
142